Exercise Genomics encompasses the translation of exercise genomics into preventive medicine by presenting a broad overview of the rapidly expanding research examining the role of genetics and genomics within the areas of exercise performance and health-related physical activity.
While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future.
Ischemic brain damage represents a major source of morbidity and mortality in westernized society and poses a significant financial burden on the health care system.
Hematopathology: Genomic Mechanisms of Neoplastic Diseases will keep physicians abreast of the rapid and complex changes in genomic medicine, as exemplified by the molecular pathology of hematologic malignancies.
Molecular Diagnostics in Dermatology and Dermatopathology presents the basics of molecular biology and molecular diagnostic methods most commonly used in the clinical laboratory, with an emphasis on the concepts and testing most relevant to dermatological diseases.
The role of free radicals and oxidative stress in neurological disorders has only recently been recognized, leaving clinical neurologists to seek in vain for information on the subject even in major textbooks.
Nanomedicine is clinical medicine with the application of nanobiotechnology, which is currently being used to research the pathomechanism of disease, refine molecular diagnostics, and aid in the discovery, development and delivery of drugs.
In keeping with goal and style of the Handbook in Modern Biophysics series, the proposed book will maintain a chapter structure that contains two parts: concepts and biological application.
Collecting an extensive amount of information from thousands of publications by leading investigators in this rapidly developing field, The Genetics and Molecular Biology of Neural Tumors provides a convenient and up-to-date one volume source for research in neural tumors of various cellular origins.
Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules.
Molecular Genetic Pathology presents up-to-date material containing fundamental information relevant to the clinical practice of molecular genetic pathology.
The collection of systems represented in Sourcebook of genomic programs, although this work is certainly well Models for Biomedical Research is an effort to re?
New discoveries in biology are occurring at an incredible rate, and with these discoveries arise nearly unimaginable opportunities in every area of human existence.
Biomedical Ethics Reviews * 1989 is the seventh volume in a series of texts designed to review and update the literature on issues of central importance in bioethics today.
The National Science Foundation, The National Institute of Occupational Safety and Health, and the Center for Technology and Humanities at Georgia State University sponsored a two-day national conference on Moral Issues and Public Policy Issues in the Use of the Method of Quantitative Risk Assessment ( QRA) on September 26 and 27, 1985, in Atlanta, Georgia.
A powerful collection of readily reproducible cutting-edge techniques for characterizing the ligand or substrate binding of neurotransmitter receptors and transporters.
Biomedical Ethics Reviews * 1987 is the fifth volume in a series of texts designed to review and update the literature on issues of central importance in bioethics today.
The practice of medicine is both learned and advanced through the compilation and study of cases -- vignettes that record the presentation, diagnosis, and treatment of individual patients and diseases.
After 18 years since the first biosimilar was approved, a lot has changed, from the regulatory guidelines to the stakeholder perceptions about the safety and efficacy of biosimilars.
Examines Critical Decisions for Transitioning Lab Science to a Clinical SettingThe development of therapeutic pharmaceutical compounds is becoming more expensive, and the success rates for getting such treatments approved for marketing and to the patients is decreasing.
Now viewed as its own scientific discipline, clinical trial methodology encompasses the methods required for the protection of participants in a clinical trial and the methods necessary to provide a valid inference about the objective of the trial.
The US Food and Drug Administration's Report to the Nation in 2004 and 2005 indicated that one of the top reasons for drug recall was that stability data did not support existing expiration dates.
Useful Statistical Approaches for Addressing Multiplicity IssuesIncludes practical examples from recent trials Bringing together leading statisticians, scientists, and clinicians from the pharmaceutical industry, academia, and regulatory agencies, Multiple Testing Problems in Pharmaceutical Statistics explores the rapidly growing area of multiple comparison research with an emphasis on pharmaceutical applications.
The increased use of non-inferiority analysis has been accompanied by a proliferation of research on the design and analysis of non-inferiority studies.
Bayesian analyses have made important inroads in modern clinical research due, in part, to the incorporation of the traditional tools of noninformative priors as well as the modern innovations of adaptive randomization and predictive power.
Randomised Response-Adaptive Designs in Clinical Trials presents methods for the randomised allocation of treatments to patients in sequential clinical trials.
Pharmacy Research: A How-To Guide for Students, Residents, and New Practitioners provides an introduction to research methods and a foundation on which individual research practices can be built.
With the prevalence of viral diseases causing significant health challenges and the emergence of highly infectious and difficult-to-treat conditions, such as Ebola, HIV/AIDS, and Hepatitis B, there is a pressing need for effective antiviral treatments.
